Evoke plc (EIHDF)
OTCMKTS · Delayed Price · Currency is USD
0.9500
0.00 (0.00%)
Jul 30, 2025, 8:00 PM EDT

Ligand Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
4163445464671,5181,438
Upgrade
Market Cap Growth
-36.98%-36.98%16.88%-69.24%5.62%78.77%
Upgrade
Enterprise Value
2,5192,2602,3601291,3621,319
Upgrade
Last Close Price
0.950.751.141.024.074.10
Upgrade
PE Ratio
----22.47127.22
Upgrade
PS Ratio
0.190.160.250.311.571.69
Upgrade
PB Ratio
-3.47-2.876.392.449.019.56
Upgrade
P/TBV Ratio
----2242.80-
Upgrade
P/FCF Ratio
1.501.242.98-12.147.40
Upgrade
P/OCF Ratio
1.471.212.83-11.617.01
Upgrade
EV/Sales Ratio
1.081.031.080.091.411.55
Upgrade
EV/EBITDA Ratio
9.039.986.100.519.4110.29
Upgrade
EV/EBIT Ratio
24.0422.5424.581.2212.5011.88
Upgrade
EV/FCF Ratio
9.068.1312.87-10.896.78
Upgrade
Debt / Equity Ratio
-19.13-19.1326.0611.250.180.22
Upgrade
Debt / EBITDA Ratio
8.668.665.768.600.210.25
Upgrade
Debt / FCF Ratio
8.268.2612.14-0.250.17
Upgrade
Asset Turnover
0.650.650.600.741.881.85
Upgrade
Quick Ratio
0.580.580.580.610.870.88
Upgrade
Current Ratio
0.650.650.670.700.950.92
Upgrade
Return on Equity (ROE)
---57.62%-85.02%42.45%7.17%
Upgrade
Return on Assets (ROA)
1.85%1.85%1.65%3.28%13.25%15.09%
Upgrade
Return on Capital (ROIC)
2.82%2.82%2.50%5.25%35.51%34.58%
Upgrade
Return on Capital Employed (ROCE)
4.00%4.00%3.60%3.90%54.30%59.10%
Upgrade
Earnings Yield
-57.83%-69.86%-15.21%-31.08%4.45%0.79%
Upgrade
FCF Yield
66.87%80.78%33.60%-10.08%8.24%13.52%
Upgrade
Dividend Yield
----1.06%3.32%
Upgrade
Payout Ratio
----79.53%202.54%
Upgrade
Buyback Yield / Dilution
0.34%0.34%-5.73%-12.93%-0.44%-1.83%
Upgrade
Total Shareholder Return
-0.34%-5.73%-12.93%0.63%1.49%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.